Design and synthesis of some new heterocyclic benzylidene hydrazide derivatives for their antileishmanial activity

Year 2013, Volume: 17 Issue: 2, 131 - 137, 07.03.2014

Ritesh Bhole , Prashant Patil Pritam Agale Sanjay Wate

Abstract

ABSTRACT: Benzylidene hydrazide is a highly active moiety against Leishmania donovani,
and has become a core structure for the design of new antileishmanial agents. The
5-nitrothiophen-2-yl-benzylidene hydrazide derivative presents a potent IC50 value. With
this background, it is attempted to discern the structural and physicochemical requirements
for the inhibition of Leishmania donovani. The techniques of quantitative structure activity
relationship and docking are valuable molecular modeling tools for drug design. In the
present study, 3-DQSAR of some Leishmania donovani inhibitors was carried out using VLife
MDS, while interaction studies were carried usind Schrodinger molecular modeling interface.
The developed QSAR models showed q2 = 0.9849, pred_r2 = 0.6770 with kNN analysis by
stepwise forward and backward method. Docking study revealed important interactions of
designed compounds with the active binding site of Leishmania donovani. Designed
compounds were synthesis and screened against Leishmania donovani. Three compounds
exhibited IC50 values lower than standard drugs. Brief SAR analysis revealed that substitution
is important to the activity.
KEY WORDS: benzylidene hydrazide derivatives, antileishmanial activity, 3D-QSAR, docking

Keywords

benzylidene hydrazide derivatives, antileishmanial activity, 3D-QSAR, docking

Design and synthesis of some new heterocyclic benzylidene hydrazide derivatives for their antileishmanial activity

Abstract

References

• Berman J. Chemotherapy of leishmaniasis: recent advances in the treatment of visceral disease. Curr Opin Infect Dis 1998; 11:707–10.
• Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15: 593-98. Desjeux P. Leishmaniasis: Public health aspects and control. Clin Dermatol 1996; 14: 417-23.
• Reithinger R, Dujardin JC, Louzir G, Pirme C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infec Dis 2007; 7:581-96.
• Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007; 14:1153-69.
• Alvar J, Canavate C, Gutierrez-Solar H, Jimenez M, Laguna F, Lopez-Velez V, Molina RJ. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10: 298-319.